319 related articles for article (PubMed ID: 7684585)
1. [Determination of tumor markers in the diagnosis of prostatic cancer].
Casas Terrón E; Mari Ruiz M; Molina Andreu E
Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
3. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
5. PSA excess in the differential diagnosis of prostate carcinoma.
Díaz F; Morell M; Rojo G
Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
[TBL] [Abstract][Full Text] [Related]
6. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
[TBL] [Abstract][Full Text] [Related]
8. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
10. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
12. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
Pagani F; Zambolin T; Bonora R; Panteghini M
J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
[TBL] [Abstract][Full Text] [Related]
14. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
15. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
16. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
[TBL] [Abstract][Full Text] [Related]
17. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
18. [Effects of prostatic massage on serum levels of prostatic acid phosphatase and specific antigen].
Sahin A; Ozen H; Balbay D; Bircan K; Koray Z; Karaagaoglu E; Remzi D
Bull Cancer; 1992; 79(11):1097-100. PubMed ID: 1284587
[TBL] [Abstract][Full Text] [Related]
19. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
20. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
